

## Author Guidelines

### Focus and scope

The *Trends in Peptide and Protein Sciences* is a peer-reviewed, print-online, scientific journal owned by Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, and documents all important aspects of research in peptides and proteins, focusing on analytics and impurities, bioinformatics, biopharmaceuticals and vaccines, biotechnology, chemical synthesis, conformational analysis, design and development of protein therapeutics, determination of structure, enzymology, folding and sequencing, formulation and stability, function, genetics, immunology, kinetics, modeling, molecular biology, pharmacokinetics and pharmacodynamics of therapeutic proteins and antibodies, pharmacology, protein engineering and development, protein-protein interaction, proteomics, purification/expression/production, simulation, thermodynamics and hydrodynamics, and protein biomarkers. This journal aims to publish high quality original research articles, reviews, short communications, and letters and to provide a medium for scientists and researchers to share their findings in the area of peptides and proteins.

### Electronic submission of a manuscript

Manuscripts must be submitted online by the Corresponding Author to the *Trends in Peptide and Protein Sciences* at:

<http://journals.sbmu.ac.ir/protein/about/submissions#onlineSubmissions>.

First-time users are required to register at <http://journals.sbmu.ac.ir/protein/user/register> before submitting a manuscript. Straightforward login and registration procedures can be found on the website.

**Note:** you should mark "Author" as your role on "My Profile".

By submission, the author(s) confirms that the manuscript (or any parts of it) has not been published previously or is not under consideration for publication in another journal. The previous presentation in any congresses should be mentioned as a footnote in the Title page and also stated in the Covering Letter. Furthermore, any illustrations, structures, or tables that have been published elsewhere must be reported, and copyright permission for reproduction must be obtained.

### Categories of articles

The *Trends in Peptide and Protein Sciences* publishes the articles in the following categories:

- **Original research articles** should be divided into the following sequence of sections: *Title page, Abstract, Keywords, Highlights, Introduction, Materials and Methods, Results and Discussion, Conclusion, Ethical Statement, Author's Contribution, Funding, Competing Interests and References, Figure captions, Figures and Tables.*

- **Review articles** inform readers of the state-of-the-art of a particular area and provide a critical view or a historical perspective. They should be comprehensive, critical, and balanced. These are contributed by scientists who are leading specialists in their field of expertise, normally at the invitation of the Editors. Authors wishing to contribute a review paper are advised first to contact one of the members of the Editorial Board.
- **Mini-reviews** with the range of 7000-10000 words, which include at least 75 references (excluding figures, structures, photographs, schemes, tables, etc.), will be published.
- **Systematic reviews**, as the highest quality evidence on a research topic, are prepared with the purpose of delivering a summary of all the already available published research in response to a research question. Systematic reviews should be prepared with a minimum of 100 references (excluding figures, structures, photographs, schemes, tables, etc.), according to PRISMA Guidelines ([www.prisma-statement.org](http://www.prisma-statement.org)).
- **Book reviews** on both recently printed and electronically relevant books will be published by the journal. For arrangement, book review proposals (including the title of the book, publisher, year of publication, and book summary) should be sent initially to the Editor-in-Chief of the journal. Suggestions are welcome.
- **Short communications** are reserved for short reports of highly important and noteworthy findings in protein and peptide sciences, useful computer software along with a description of relevant applications, and the announcement of novel protocols. Short communications should not exceed 2500 words in length, including references, tables and figures. These manuscripts will be peer-reviewed and considered for fast publication if accepted.
- **Letter to the Editors** is intended to stimulate a discussion in areas of general concern and controversy in protein and peptide sciences. They should be written in a continuous style and should normally not exceed 1500 words in length and contain no more than one figure or table.

### **Covering letter**

All manuscripts must be accompanied by a signed cover letter in the “Comments for the Editor” and submitted by the Corresponding Author during online submission. Other than any comments you would like to write to the editor, the following items must be addressed in this letter; the importance of the work and its relevance to the journal’s scope, name, address, telephone number, fax number, and e-mail address of the Corresponding Author. The author has to confirm in writing that the manuscript (or any parts of it) has not been published previously or is not under consideration for publication in another journal. The previous presentation in any congresses should be stated in the covering letter. You are also required to mention the names of at least two potential preferred referees that could be considered for reviewing your manuscript.

### **Highlights**

Highlights are required for this journal. They consist of a short collection of bullet points that convey the core findings of the manuscript, including 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point), and should be submitted on a separate page following the Title page.

### **Graphical abstract**

A colored graphic could be included with each manuscript. This must be presented on a separate page following the Abstract (preferred file types are TIFF, PNG, JPEG and Power Point, minimum 300 dpi). A graphical abstract, not exceeding 30 words along with the illustration, helps to summarize the contents of the manuscript in a concise pictorial form.

### **Preparation of manuscripts**

#### **General instructions**

Manuscripts should be prepared according to the following mentioned stylistics. The Editors have the right to make editorial corrections and additional changes with the knowledge and approval of the Corresponding Author. The word processing format for the manuscript file must be Microsoft Word. The main manuscript should contain:

#### ***- Title Page***

The title page should include:

- a concise and informative title:
- the name(s) of the author(s),
- the affiliation(s) of the author(s),
- the e-mail address of the authors,
- the ORCID ID of the authors or at least the first and corresponding authors,
- the e-mail address, ORCID ID, telephone, and fax numbers of the Corresponding Author
- a running title (short comprehensive title contains a maximum of 85 characters).

The title of the article should be precise and brief. Authors should avoid the use of non-standard abbreviations. Use an initial capital letter for each title word. The authors will be required to provide their full names and institutional affiliations by numbers in superscripts. The Corresponding Author should be remarked with a superscripted asterisk. Authors are expected to consider carefully the list and order of authors before submitting their manuscript.

#### ***- Abstract***

The abstract of an article should be a clear, concise and accurate summary of the work, having no more than 300 words. Use of abbreviations should be avoided and the references should not be cited in the abstract.

### **- Keywords**

Authors should provide 4 to 6 keywords, which can be used for indexing purposes. They should be in alphabetic order and first capital letter, separated with semicolons.

### **- Abbreviations (if required)**

The full term of each abbreviation should be written in the text before its first use. Standard and well-known abbreviations do not need explanation. All nomenclature, including gene names and symbols, should be used in a scientifically accurate manner following the nomenclature conventions adopted by the scientific community.

### **- Main text**

When submitting a manuscript, ensure that the following sections are included separately; *Introduction, Materials and Methods, Results and Discussion, Conclusion, Acknowledgements, Ethical Statement, Author's Contribution, Funding, Competing Interests and References, Figure captions, Figures and Tables*. The *Introduction* should be concise, without subheadings, indicating the purpose and the rationale of the study. *Materials and Methods* provide sufficient details to allow the work to be reproduced, with details of the suppliers and catalog number when appropriate. Methods already published should be indicated by a reference, only relevant modifications should be described. *Discussion* should explore the significance of the results of the work, not repeat them. It may contain subheadings in some sections. The detailed data should not be repeated in *Conclusion*. In the case of Short Communications, *Results and Discussion* and *Conclusion* could be merged.

### **- Acknowledgements**

All contributors who do not meet the criteria for authorship should be covered in this section. Financial and material supports should also be acknowledged.

### **- Competing Interests**

Author(s) warrants that any financial interest, direct or indirect, that exists or may be perceived to exist for individual contributors in connection with this manuscript has been disclosed in the Covering Letter and Manuscript.

### **- Ethical consideration**

Author(s) herein confirms that all human and/or animal studies undertaken are in compliance with the regulations of their institution(s) and generally accepted guidelines governing such work. In any studies that involve experiments on human subjects, work must be conducted in accordance with the [Declaration of Helsinki](#). For the experiments on animal subjects, the compliance with [National Institutes of Health Guidelines for the Human Use of Laboratory Animals](#) should be declared in the text.

Authors warrants that this manuscript contains no violation of any existing copyright or other third party right or any materials of an obscene, indecent, libelous, or otherwise unlawful nature and that to the best of their knowledge, the manuscript does not infringe the rights of others.

### ***- Authors' contribution***

All persons who are listed as authors must certify that they have participated sufficiently in the work and take public responsibility for the content of appropriate portions.

#### *Example of authors' contribution statement*

A.B. and B.C. conceived of the presented idea. A.B. developed the theory and performed the computations. C.D. and D.E. verified the analytical methods. B.C. encouraged A.B. to investigate [a specific aspect] and supervised the findings of this work. All authors discussed the results and contributed to the final manuscript.

### ***- Funding support***

Financial and material support should be acknowledged, here.

### ***- References***

All references should be listed in accordance with the Harvard style. Harvard is an "author/date" system, so your in-text citation consists of the author(s) and year of publication. In the end, the authors should be listed in alphabetical order. For more guides, use the online information at <http://guides.is.uwa.edu.au/harvard>.

If using *EndNote*, cite according to the Author-Date style.

#### **• *In-text citation***

For Harvard in-text citation, the last name of the author(s) and the year of publication appear in parenthesis beside any quotation or paraphrase of a source.

#### *✓ Single citation*

<i>Number of authors</i>	<i>In-text citation example</i>
1 author	(Davis, 2019)
2 authors	(Davis and Barrett, 2019)
+3 authors	(Davis et al., 2019)

#### *✓ Multiple citations at the same point*

When you need multiple citations to appear at the same point in your text – for example, when you refer to several sources with one phrase – you can present them in the same set of parenthesis, separated by semicolons. List them in order of publication date.

*Example*

(Gillner, *et al.*, 2009; Uda and Creus, 2011; Greenfield and Harlow, 2014; Starus, *et al.*, 2015).

✓ *Multiple sources with the same author and date*

If you cite multiple sources by the same author, which was published in the same year, it is important to distinguish between them in your citations. To do this, insert an 'a' after the year in the first one you reference, a 'b' in the second, and so on.

*Example*

.... (Woodhouse, 2018a) while .... (Woodhouse, 2018b) ...

✓ *No author (standards, online reports, governmental publications and pharmacopeial catalogs)*

When a source lacks an identified author, there is often an appropriate corporate source – the organization responsible for the source – whom you can credit as the author instead, as in the Google and Wikipedia examples above.

*Example*

(Collins English dictionary, 2012) or (WHO, 2020), (BP, 2018).

✓ *Conference papers/ proceeding*

Galar et al. (2014) identified the risks of...SMART risk assessments...(Galar et al. 2014).

- ❖ If the author(s) name appears in the text as part of the body of the assignment, then the year will follow in round brackets, e.g. According to Smith (2017).

• *Citation in reference/ bibliography*

*Note that all citations should have the DOI if available.*

✓ *Journal articles*

Bernocchi, B., Carpentier, R., Lantier, I., Ducournau, C., Dimier-Poisson, I. and D. Betbeder, (2016). "Mechanisms allowing protein delivery in nasal mucosa using NPL nanoparticles." *Journal of Controlled Release*, **232**: 42–50. DOI: <https://doi.org/10.1016/j.jconrel.2016.04.014>.

Bates, R. C., Stith, B. J. and K. E. Stevens, (2015). "Increasing pro-survival factors within whole brain tissue of Sprague Dawley rats via intracerebral administration of modified valproic acid." *Journal of Pharmacological Sciences*, **128**(4): 193-201. DOI: <https://doi.org/10.1016/j.jphs.2015.07.003>.

✓ *Book*

Narhi, L.O. (2013). "*Biophysics for therapeutic protein development*." Vol. 4, Springer Science & Business Media, CA, USA, pp. 119-159.

Silbey, R. J., Alberty, R. A. and M. G. Bawendi, (2005). *"Physical Chemistry."* 4<sup>th</sup> ed., John Wiley & Sons, Inc., New Jersey, pp. 74-101.

✓ *Book chapter*

– *One author*

Chien, Y. W. (1991). "Transdermal Route of Peptide and Protein Drug Delivery." In: V. H. L. Lee (Ed.), *Peptide and Protein Drug Delivery*, Marcel Dekker, Inc., New York, pp. 667-689.

– *Two authors*

Pearlman, R. and T. H. Nguyen, (1991). "Analysis of Protein Drugs." In: V. H. L. Lee (Ed.), *Peptide and Protein Drug Delivery*, Marcel Dekker, Inc., New York, pp. 247-301.

– *Three and more author*

Banerjee, P. S., Hosny, E. A. and J. R. Robinson, (1991). "Parenteral Delivery of Peptide and Protein Drugs." In: V. H. L. Lee (Ed.), *Peptide and Protein Drug Delivery*, Marcel Dekker, Inc., New York, pp. 487-543.

✓ *Conference Paper/ Proceeding*

– *Paper*

Galar, D., Sandborn, P., Kumar, U. and C–A. Johansson, (2014). "SMART: integrating human safety risk assessment with Asset Integrity." In: G. Dalpiaz, R. Rubini, G. D'elia, M. Cocconcelli, F. Chaari, R. Zimroz, W. Bartelmus and M. Haddar, eds. *Advances in condition monitoring of machinery in non–stationary operations, proceedings of the third international conference on condition monitoring of machinery in non–stationary operations*, CMMNO, 2013, Ferrara, Italy. Berlin: Springer, pp. 37–59.

Redknap, M. (2004). "Viking–age settlements in Wales and the evidence from Llanbedrgoch." In: J. Hines, A. Lane and M. Redknap, eds. *Land, sea and home, proceedings of a conference on Viking–period settlement*, July 2001, Cardiff. Leeds: Manay Publishing, pp. 139–175.

– *Proceeding*

Dalpiaz, G., Rubini, R., D'elia, G., Cocconcelli, M., Chaari, F., Zimroz, R., Bartelmus, W. and M. Haddar, eds., (2014). *"Advances in condition monitoring of machinery in non–stationary operations, proceedings of the third international conference on condition monitoring of machinery in non–stationary operations,"* CMMNO, 2013, Ferrara, Italy. Berlin: Springer.

Orman, W. and M.J. Valleau, eds., (2014). *"Proceedings of the 38th annual Boston University Conference on language development," 2013, Boston, Massachusetts.* Somerville, MA; Cascadilla Press. Volume 2.

✓ *Dissertation*

Liu, Z. (2012). *"Metabolic Engineering of Recombinant Protein Production by Saccharomyces cerevisiae."* Göteborg: Chalmers University of Technology, Sweden.

✓ *Web page*

Cohen, N. (2009). *DNA, RNA and protein formation: Track 1.* Available at: <http://www.open.edu/openlearn/science-maths-technology/science/biology/dna-rna-and-protein-formation> (accessed 2016-09-12).

✓ *Patent*

Name of inventor (if applicable) (Year patent granted). *"Title of patent."* Applicant of patent. Date patent granted (if applicable). Date of application. Official patent series Patent Serial Number.

*Example*

Hollis T. J. and F. Tan, (2017). "Helical gradient coil for magnetic resonance imaging apparatus." *GE Medical Systems Global Technology Company LLC.* 10 January. Appl: 20 August 2012. GB Patent GB2494259.

✓ *Online reports*

Use "World Health Organization" as the author. Place the year next. Add the title of the report next. Place the website at the end.

*Example*

World Health Organization. (2020, September 22). "Tobacco responsible for 20% of deaths from coronary heart disease." Retrieved from <https://www.who.int/news-room/detail/22-09-2020-tobacco-responsible-for-20-of-deaths-from-coronary-heart-disease>

✓ *Government publications*

Government Agency OR Last name, First Initial., (Year published). *Title of document or article.* City published: Publisher, Page(s).

*Example*

Pennsylvania Department of Transportation, (2012). *BicyclePA Routes.* Harrisburg: PENNDOT, p.1.

✓ *Standards*

Organisation Responsible for the Standard. Standard number - Name of standard [Internet]. Year [revision DD Mon YYYY; cited YYYY Mon DD]. Available from: URL

*Example*

Australia New Zealand Food Standards Code. Standard 1.2.5 - Date marking of packaged food [Internet]. 2012 [revised 11 Oct 2012; cited 2019 May 20]. Available from: <http://www.comlaw.gov.au>

Standards Australia. AS ISO 15189-2013 - Medical laboratories: requirements for quality and competence [Internet]. 2013 [cited 2019 Jan 15]. Available from: <https://www.saiglobal.com>

✓ *Pharmacopoeia (print)*

Title of work. Edition. Vol. #, volume name. Place of publication: Publisher; Year of publication. Entry title; Page/s of entry.

*Example*

British Pharmacopoeia. Vol. 1. London: Medicines and Healthcare Products Regulatory Agency; 2018. Disodium hydrogen phosphate; p. 833-4.

The United States Pharmacopoeia. National formulary. Vol. 1. Rockville (MD): United States Pharmacopoeial Convention; 2017. Collodion; p. 1076

- **Tables and Figures** should be embedded at the end of the manuscript file. They must be cited in the text consecutively with Arabic numerals (Figure 1 or Table 1) and presented on separate pages. Accepted File formats for figures are TIFF, PNG and JPEG at 600 dpi or higher. Graphs and charts are considered equal to figures and accepted in the formats of TIFF, PNG and JPEG. Tables should be in Word Table format, not inserted as graphics. They should be self-explanatory and cited in the main text. Tables with their captions should be presented following the References on a separate page. A table caption should be a brief descriptive title and all other important information must be presented in the footnotes. Add Figures and Figures' captions separately following the Tables. Equations must be presented by the equation tab of Word. Chemical structures and reactions are presented by schemes. Equations and Schemes should also be cited sequentially with Arabic numerals (Equation 1 or Scheme 1).

### **Publication Ethics**

*TPPS* follows international regulations against scientific misconduct including fabrication, falsification, [plagiarism](#), etc. Any cases of suspected misconduct will be assessed during the peer-review and publication process based on [COPE Guidelines](#).

Plagiarism happens when someone presents works/ideas of others as his/her own, without full citation or acknowledgement. All submitted manuscripts have to be original and should have less than 20% similarity in text with other publications. Manuscripts will be checked by appropriate plagiarism checking software.

After submission, the authorship confirmation letters will be emailed to all authors. They should notify the Editorial Office if any misconduct has happened. The Editor-in-Chief or section Editors evaluate the submitted files before the peer-review process, and the manuscript will then be sent back to the author if do not have approval criteria or have plagiarism. In this step, authors can revise the manuscript and resubmit it. If they do not revise, the manuscript will be rejected.

If Editors discover any misconduct including fabrication, falsification, and plagiarism after publication, the manuscript will be withdrawn. Authors (at least the Corresponding Author) should

have close collaboration and communication with the Editorial Office during the publication process and after, if needed.

## **Authorship**

According to the ICMJE recommendation, authorship is based on the following four criteria:

- substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data for the work, **AND**
- drafting the work or revising it critically for important intellectual content, **AND**
- final approval of the version to be published, **AND**
- agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved [<https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>].

Therefore, all authors should make substantial contributions to all of the followings: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

## **Authors' Agreement Form**

It is mandatory that a signed [Authors' Agreement Form](#) be sent along with the proofreading by the Corresponding Author. The authors acknowledge that the publisher has the legal right to take appropriate action against the authors for any violation of the terms and conditions as laid down in the Authors' Agreement Form.

## **Authors' responsibility**

As part of the submission process, authors are required to check off their submission's compliance with all of the following items. Submissions may be returned to authors that do not adhere to these guidelines.

1. The submission has not been previously published, and is not under consideration for publication in another journal.
2. The submission file is in OpenOffice, Microsoft Word document file format.
3. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which are found in "About the Journal."
4. The ORCID ID of the authors or at least the first and the corresponding authors are assigned.
5. One author has been designated as the corresponding author with contact details: E-mail address, full postal address, phone numbers
6. All necessary parts are considered and the manuscript contains Highlights, Title page, Abstract and Keywords, Running Title, Main manuscript, Figure captions, all figures, all tables.

7. The manuscript has been 'spell-checked' and 'grammar-checked'
8. All references mentioned in the Reference list are cited in the text, and vice versa. References are in the correct format for this journal.
9. Permission has been obtained for use of copyrighted material from other sources.
10. A covering letter with all needed items is prepared

### **Changes to authorship**

Authors should consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list can be made only before the manuscript has been accepted, only if the journal Editor approves. To request such a change, a letter from the corresponding author should be sent to the Editorial Office, containing: (a) the reason for the change in the author list, and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only on exceptional occasions, the Editor will approve the addition, deletion, or rearranging authors' list after the acceptance of the manuscript. The release of the manuscript will be suspended while the editor is reviewing the request. If the manuscript has already been published in an online issue, any request approved by the Editor will result in an erratum.

### **Page charges**

There are no charges for publication in this Journal.

### **Copyright notice**

Upon publication, the authors agree that the journal of *Trends in Peptide and Protein Sciences (TPPS)* is the copyright owner of the material published. All works published in the TPPS are open access and are available to anyone on the website of the journal without cost. The users are free to use the work, subject to proper attribution of authorship and ownership of the rights. Authors may use their material in presentations and subsequent publications they write or edit themselves, provided that the TPPS is referenced in writing and is acknowledged as the original publication.

### **Creative Common Attribution Non-Commercial 4.0 International License (CC BY-NC 4.0)**

This is an open access journal in which the articles are distributed under the terms of [Creative Common Attribution Non-Commercial 4.0 International License](https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

### **Privacy Statement**

The names and email addresses entered in the journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purposes or to any other parties.

### **Preprint policy**

A preprint is considered an author's version of a manuscript before the version is accepted for publication in a journal. Authors are allowed to deposit an initial draft of their manuscript anywhere. However, authors should disclose the Digital Object Identifier (DOI) once the manuscript is submitted to the journal or at any other point during the peer review process at TPPS. If the manuscript is accepted for publication, the preprint record should be updated with the DOI and a URL link to the published version of the article on the journal website. Please note that however, deposition of a preprint shall not be viewed as prior publication.